Scarica l'app Stockscreener
1.53
2.00%
0.03
Pre-mercato:
1.52
-0.01
-0.65%
Beyondspring Inc Borsa (BYSI) Ultime notizie
Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI) - Defense World
Breakout Zone: How BeyondSpring Inc stock compares to market leaders2025 EndofYear Setup & Short-Term Trading Alerts - moha.gov.vn
Why BeyondSpring Inc. stock could benefit from AI revolutionVolatility Index Analysis & Free Significant Capital Appreciation - bollywoodhelpline.com
S P Trends: Does BeyondSpring Inc stock trade at a discount to peersMarket Movement Recap & Precise Swing Trade Alerts - moha.gov.vn
BeyondSpring Inc. (NASDAQ:BYSI) Sees Large Increase in Short Interest - MarketBeat
BeyondSpring (NASDAQ:BYSI) Shares Down 4.2% – Should You Sell? - Defense World
BeyondSpring (NASDAQ:BYSI) Trading Down 4.2%Should You Sell? - MarketBeat
Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Krystal Biotech (NASDAQ:KRYS) and BeyondSpring (NASDAQ:BYSI) Critical Survey - Defense World
Will BeyondSpring Inc. stock benefit from infrastructure spendingJuly 2025 Trade Ideas & Consistent Growth Equity Picks - Улправда
Can BeyondSpring Inc. stock weather global recessionJuly 2025 Breakouts & Weekly Return Optimization Alerts - Улправда
Will BeyondSpring Inc. stock benefit from sector rotationJuly 2025 Macro Moves & Breakout Confirmation Alerts - DonanımHaber
Will BeyondSpring Inc. stock benefit from AI adoptionMarket Weekly Review & Weekly Chart Analysis and Guides - Улправда
Pharma News: Will BeyondSpring Inc. stock outperform tech sector in 2025Quarterly Trade Summary & Low Risk Investment Opportunities - moha.gov.vn
Beyondspring Delays Second Closings of Share Sale - TipRanks
BeyondSpring Inc. Announces Preferred Share Purchase Agreement - TradingView — Track All Markets
BeyondSpring (NASDAQ: BYSI) now expects SEED share Second Closings in 1H 2026 - Stock Titan
BYSI: Recent Business Developments Shape Market Outlook - StocksToTrade
BeyondSpring Inc. Stock Shows Upward Spike As Earnings Report Uncovers Surprises - StocksToTrade
BeyondSpring Stock Faces Challenges Amid Recent Market Dynamics - timothysykes.com
BeyondSpring Inc. Faces Financial Pressure in the Pharmaceutical Market - timothysykes.com
BYSI Stock Shows Turbulence Amid Financial Uncertainty - StocksToTrade
BYSI Stock Volatility Amidst Strategic Developments and Market Shifts - StocksToTrade
BeyondSpring presents phase 3 DUBLIN-3 data at ESMO Asia Congress - MSN
BYSI’s Stock Roller Coaster: What Happens Next? - StocksToTrade
BeyondSpring Inc.’s Market Shift: Analyzing Financial Trends and Price Movements - timothysykes.com
BeyondSpring’s Stock Gains Steam Amid Market Developments - timothysykes.com
BeyondSpring Inc. (BYSI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BeyondSpring (BYSI) Stock :Surges 5% as New Plinabulin Data Strengthens Case for Global NSCLC Registration Path - CoinCentral
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 - marketscreener.com
BYSI: BeyondSpring's Plinabulin Shows Promising Results in Phase 3 Trial - GuruFocus
BeyondSpring stock rises after positive Asian subset data from lung cancer trial - Investing.com Nigeria
BeyondSpring stock rises after positive Asian subset data from lung cancer trial By Investing.com - Investing.com South Africa
BeyondSpring reports positive Asian subset data for lung cancer drug By Investing.com - Investing.com Canada
BeyondSpring reports positive Asian subset data for lung cancer drug - Investing.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewswire
BeyondSpring’s Plinabulin combination shows survival benefit in NSCLC - TipRanks
BeyondSpring (BYSI) Reports Promising Results for Plinabulin in Lung Cancer Study - GuruFocus
BeyondSpring Announces Positive Phase 3 DUBLIN-3 Results for Plinabulin in NSCLC Patients Post Anti-PD-(L)1 Therapy and Plans for Global DUBLIN-4 Trial - Quiver Quantitative
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 - marketscreener.com
BeyondSpring (NASDAQ: BYSI) DUBLIN-3 finds 15.8-month OS, fewer brain mets in NSCLC - Stock Titan
Why 22nd Century Group Inc stock could benefit from AI revolutionTrade Ideas & Accurate Buy Signal Notifications - moha.gov.vn
BeyondSpring Inc. Reports Q3 2025 Earnings and Strategic Shift - MSN
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):